ArticleFrontiers in immunology2025
Identifying common genetic etiologies between iridocyclitis and related immune-mediated diseases.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with iridocyclitis are at heightened risk for immune-mediated diseases. The genetic underpinnings of iridocyclitis are intricate, necessitating an integrated approach to unravel the genetic connections between iridocyclitis and these diseases. Methods: GWAS data were integrated from three databases using METAL. Independent risk loci were analyzed through conditional and joint genome-wide multi-trait analysis, multi-marker genomic annotation, and functional mapping of significant loci. This approach combined quantitative trait loci data and various methodologies to identify genes and proteins associated with risk. Target gene verification was conducted through cell experiments and flow cytometry. Results: The study identified five independent iridocyclitis-related risk loci and 123 associated genes. Additionally, 14 multi-disease risk genes and 109 disease-related proteins were discovered. Flow cytometry confirms that FBXL18 and IL15RA are responsive to inflammatory stimuli and supports their role in immune-mediated pathways relevant to iridocyclitis, underscoring its potential as a therapeutic target. Conclusion: This study indicates that the polygenic factors shared between iridocyclitis and immune-mediated diseases are broadly distributed across the genome. These findings affirm a genetic link between iridocyclitis and immune-mediated diseases and highlight new therapeutic targets for these conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.